We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The use of artificial intelligence and machine learning in drug development has been ramping up and investors are taking keen notice of the growing trend.
Cytoreason uncovers a unique biomarker that can predict who will respond and who will not to anti TNF drugs helping thousands of patients gain proper treatment